063 Autoimmunity and disease outcomes of COVID-19, lessons from vitiligo patients

por Post, N., Bekkenk, M., Luiten, R.
Publicado 2022

Generation of chimeric bispecific G250/anti-CD3 monoclonal antibody, a tool to combat renal cell carcinoma.

por Luiten, R. M., Coney, L. R., Fleuren, G. J., Warnaar, S. O., Litvinov, S. V.
Publicado 1996

Patients’ perspective on current treatments and demand for novel treatments in vitiligo

por Narayan, V.S., Uitentuis, S.E., Luiten, R.M., Bekkenk, M.W., Wolkerstorfer, A.
Publicado 2020

Donor to recipient ratios in the surgical treatment of vitiligo and piebaldism: a systematic review

por Narayan, V.S., van den Bol, L.L.C., van Geel, N., Bekkenk, M.W., Luiten, R.M., Wolkerstorfer, A.
Publicado 2021

Ultraviolet photography in vitiligo: image quality, validity and reliability

por Uitentuis, S.E., Heilmann, M.N., Verdaasdonk, R.M., Bae, J.M., Luiten, R.M., Wolkerstorfer, A., Bekkenk, M.W.
Publicado 2020

T‐cell responses against 4‐tert‐butylphenol‐exposed pigmented cells in a patient with occupational vitiligo

por Vrijman, C., Willemsen, K.J., Tjin, E.P.M., Kammeyer, A., van den Boorn, J.G., van der Veen, J.P.W., Jungbauer, F.H.W., Kardaun, S.H., Luiten, R.M.
Publicado 2019

Effect of immunosuppressive treatment on biomarkers in adult atopic dermatitis patients

por Roekevisch, E., Szegedi, K., Hack, D.P., Schram, M.E., Res, P.C.J.M., Bos, J.D., Leeflang, M.M.G., Luiten, R.M., Kezic, S., Spuls, P.I., Middelkamp‐Hup, M.A.
Publicado 2020